Mindset’s Family 3 of next-generation psilocybin compounds have demonstrated low levels of activity at the 5-HT2A receptor and long half lives Advancing compounds into additional Proof of Concept preclinical studies to measure daily take-home viability TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”)…


Previous articleSmall Pharma Reports Fiscal Third Quarter 2021 Highlights
Next articleSilo Pharma Extends Exclusive Option Agreement for Homing Peptides